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Abstract 
Background. Hydrochlorothiazide is a cheap and effective antihypertensive agent but may cause 
hyponatremia. Even though several risk factors for hydrochlorothiazide-induced hyponatremia 
have been reported, this study aimed to evaluate additional risk factors for hydrochlorothiazide-
induced hyponatremia in hypertensive patients. 
Materials and methods. The inclusion criteria were: adult patients, diagnosed with hypertension 
and receiving hydrochlorothiazide treatment. Eligible patients were divided into two groups: 
with and without hyponatremia. Those with hyponatremia were identified by using the ICD-10 
code E871, while those without hyponatremia were patients who did not have any reported 
hyponatremia until the last visit. The ratio between hyponatremia and non-hyponatremia group 
was 1:2. Predictors for hyponatremia were analyzed by using logistic regression analysis. 
Results. During the study period, there were 68 patients admitted due to symptomatic 
hyponatremia from hydrochlorothiazide. There were four independent factors in the model 
predictive of occurrence of symptomatic hydrochlorothiazide-induced hyponatremia in 
hypertensive patients: sex, body mass index, plasma glucose, and serum albumin. Male sex, body 
mass index, and serum albumin were negatively associated with occurrence of symptomatic 
hydrochlorothiazide-induced hyponatremia in hypertensive patients with adjusted OR of 0.099, 
0.683, and 0.122, respectively. The plasma glucose had adjusted OR of 1.030 [95% CI of (1.009, 
1.051)]. 
Conclusions. Factors associated with hydrochlorothiazide-induced symptomatic hyponatremia in 
hypertensive patients were sex, body mass index, plasma glucose level, and serum albumin level. 
The latter two risk factors have never been reported as risk factors for hydrochlorothiazide-
induced symptomatic hyponatremia in hypertensive patients. 
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Introduction 
 Hypertension is a common disease in clinical practice. It was estimated that there were 
one billion hypertensive patients worldwide. Good control of blood pressure is important and can 
lower cardiovascular morbidities or mortalities particularly stroke or heart failure [1]. The Eighth 
Joint National Committee (JNC 8) recommends using thiazide as the first-line treatment for 
hypertension [2]. A post hoc analysis of ALLHAT study found that chlorthalidone was superior 
to doxazosin in terms of heart failure and stroke prevention with relative risk of 1.80 and 1.26, 
respectively [3].  
 The advantage of thiazide is it’s low cost but it may cause several side effects such as 
hyponatremia, or hypokalemia. These side effects may result in severe morbidities such as 
hospitalization to correct hyponatremia or osmotic demyelination syndrome from hyponatremia 
treatment. Several studies were conducted to evaluate risk factors of thiazide-induced 
hyponatremia in patients with hypertension [4–7]. At least three out of 10 hypertensive patients 
taking thiazide may develop hyponatremia in their lifetimes [4]. Risk factors for thiazide-induced 
hyponatremia included age, female sex, body mass index, and KCNJ1 rs2509585 C/T or T/T 
polymorphisms with adjusted odds ratio (OR) of 1.13, 4.49, 0.80, and 5.75, respectively [6]. 
Even though several risk factors for hydrochlorothiazide-induced hyponatremia have been 
reported such as obesity or advanced age, this study aimed to evaluate additional risk factors for 
hydrochlorothiazide-induced hyponatremia in hypertensive patients. 
 
Materials and methods 
This study was a retrospective analytical study. It was conducted at University Hospital. 
The inclusion criteria were: adult patients, diagnosed with hypertension and receiving 
hydrochlorothiazide treatment. The study period was between 2005 and 2014. Eligible patients 
were all adult hypertensive patients treated at the University Hospital and were divided into two 
groups: with and without symptomatic hyponatremia.  
Symptomatic hyponatremia was diagnosed in patients who had serum sodium less than 
135 mEq/L, had at least one symptom caused by hyponatremia, and required admission. Those 
patients with symptomatic hyponatremia were identified by using the ICD-10 code; E871 in 
summary discharge form of admitted patients, while those without hyponatremia were patients 
who did not have any reported hyponatremia until the last visit in December 2014. The ratio 
between hyponatremia and non-hyponatremia group was 1:2. The non-hyponatremia group was 
randomly selected from the patient list by simple random sampling method.  
Clinical data of all patients were reviewed from medical records. Baseline and clinical 
characteristics of those with and without symptomatic hyponatremia were compared using 
descriptive statistics. When appropriate, a Wilcoxon rank sum/Student’s t-test and Fisher’s exact 
tests/chi-square test were applied to compare the differences between the two groups in terms of 
numbers and proportions, respectively. Univariate logistic regression analysis was applied to 
calculate the crude odds ratio (OR) of individual variables for occurrence of symptomatic 
hyponatremia. All clinically significant variables were included in subsequent multivariate 
logistic regression analysis. Analytical results were presented as crude OR, adjusted OR, and 
95% confidence intervals. The goodness of fit of the multivariate logistic regression model was 
tested using the Hosmer–Lemeshow method. All data analysis was performed using STATA 
software (StataCorp LP, College Station, TX, USA). 
 
Results 
 During the study period, there were 68 patients admitted due to symptomatic 
hydrochlorothiazide-induced hyponatremia. The two most common presenting symptoms were 
fatigue (44 patients, 65.67%) and nausea/vomiting (39 patients, 59.09%). The other presenting 
symptoms were drowsiness (15 patients, 22.39%), hiccup (8 patients, 119.4%), headache (8 
patients, 119.4%), confusion (6 patients, 8.96%), seizure (3 patients, 4.48%), and muscle cramp 
(2 patients, 2.99%). The median serum sodium was 117 mEq/L. The median hospital stay was 3 
days (range 2–5 days). After admission, 32 patients (47.06%) did not received 
hydrochlorothiazide permanently without adding any other antihypertensive drug, while 19 
patients (27.94%) switched to other antihypertensive drugs, 14 patients (20.59%) temporarily 
stopped taking hydrochlorothiazide, 2 patients (2.94%) still received hydrochlorothiazide with 
the same doses, and 1 patient received lower dose of hydrochlorothiazide.  
 Table 1 showed clinical factors of hypertensive patients treated with hydrochlorothiazide 
categorized by presence of symptomatic hyponatremia. There were six factors significantly 
different between those with and without hyponatremia including age, sex, body mass index, 
duration of hydrochlorothiazide therapy, history of diabetes mellitus, and history of coronary 
artery disease. Those with hyponatremia had older age (73 vs. 64 years), lower percentage of 
male (23.53% vs. 37.41%), and lower body mass index (22.43 vs. 25.32 kg/m2), and shorter 
duration of hydrochlorothiazide use (12 vs. 36 months) than those without hyponatremia (Tab. 
1). 
 Regarding laboratory results, hypertensive patients treated with hydrochlorothiazide with 
hyponatremia had 15 different laboratory values from those without hyponatremia (Tab. 2). For 
example, those with hyponatremia had higher plasma glucose (132 vs. 106 mg/dL), lower eGFR 
(47.81 vs. 70.06 mL/min/1.732), and lower serum albumin level (3.9 vs. 4.2 g/dL) than those 
without hyponatremia.  
 There were four independent factors in the model predictive of occurrence of 
symptomatic hydrochlorothiazide-induced hyponatremia in hypertensive patients. These factors 
were sex, body mass index, plasma glucose, and serum albumin (Tab. 3). Male sex, body mass 
index, and serum albumin were negatively associated with occurrence of symptomatic 
hydrochlorothiazide-induced hyponatremia in hypertensive patients with adjusted OR of 0.099, 
0.683, and 0.122, respectively. The plasma glucose had adjusted OR of 1.030 (95% CI of (1.009, 
1.051). The Hosmer-Lemeshow Chi square of the final model was 5.70 (p value 0.681). 
 
Discussion 
 Among the four independent predictors for hydrochlorothiazide-induced symptomatic 
hyponatremia, two of them were similar to other previous reports including female sex [8, 9] and 
lower body mass index [5, 7, 9, 10]. Small size patients may have tremendous change in serum 
sodium due to less total body water [11]. The mechanism of association between female sex and 
diuretic-induced hyponatremia is not well understood [9].  
 A nested case-control study [12] found that thiazide may increase risk of new-onset 
diabetes by 1.54 times (95% CI of 1.41, 1.68). However, there is no previous study showing the 
association of having high plasma glucose as a risk factor for hydrochlorothiazide-induced 
symptomatic hyponatremia. Similarly, there is no previous report on albumin level on 
hydrochlorothiazide-induced symptomatic hyponatremia in literatures. Increasing of serum 
albumin by 1 gm/dL lower risk of hydrochlorothiazide-induced symptomatic hyponatremia by 
88% (Table 3). We postulate that lower albumin level may be associated with poor nutritional 
status and low intravascular volume causing hypervolemic hyponatremia. 
 Age is another risk factor for hydrochlorothiazide-induced symptomatic hyponatremia 
previously reported [9–11]. In this present study, age is not an independent factor for 
hydrochlorothiazide-induced symptomatic hyponatremia by multivariate logistic regression 
which controls for confounding factors. The median age of study population with hyponatremia 
in this study was 73 years which may similar to a previous study conducted in the elderly 
hypertensive patients [13]. The average age of participants in the previous study from the US 
was 74 years [13]. The adjusted OR (95% CI) of thiazide-induced symptomatic hyponatremia 
was 1.47 (0.98, 2.19) which was comparable with the present study. 
 There are some limitations in this study. First, the study population in this study included 
only hypertensive patients with symptomatic hydrochlorothiazide-induced hyponatremia. Those 
with mild hyponatremia who did not required hospitalization were not included. The genetic 
factor previously reported to be associated with thiazide-induced hyponatremia, KCNJ1 
rs2509585 C/T or T/T polymorphisms, were not studied. Finally, due to retrospective study 
design, some factors were missing such as history and quantity of alcohol or smoking. 
 
Conclusions 
 Factors associated with hydrochlorothiazide-induced symptomatic hyponatremia in 
hypertensive patients were sex, body mass index, plasma glucose level, and serum albumin level. 
The latter two risk factors have never been reported as risk factors for hydrochlorothiazide-
induced symptomatic hyponatremia in hypertensive patients. 
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Table 1. Clinical features of hypertensive patients treated with hydrochlorothiazide categorized 
by presence of symptomatic hyponatremia (hypoNa)  
 
Factors No hypoNa 
(n = 139) 
HypoNa 
(n = 68) 
p value 
Basic characteristics    
Age (years) 64 (55-69) 73 (65-79) < 0.001 
Male sex  52 (37.41) 16 (23.53) 0.046 
BMI [kg/mm2] 25.32 (23.32-28.13) 22.43 (21.08–25.51) < 0.001 
Alcohol drinking 12 (22.22) 6 (17.65) 0.787 
Current smoker  14 (25.45) 8 (22.22) 0.725 
Co-antihypertensive drugs    
  None 23 (17.29) 18 (26.47) 0.127 
  Calcium channel blocker 60 (45.11) 22 (32.84) 0.096 
  Beta-blocker 33 (24.81) 20 (29.85) 0.446 
  Alpha-blocker 5 (3.79) 4 (5.97) 0.488 
  ACEI 41 (30.83) 22 (32.84) 0.773 
  ARB 24 (18.05) 7 (10.45) 0.161 
  Vasodilator 3 (2.26) 5 (7.46) 0.121 
Duration of hydrochlorothiazide 
use 
36 (13-67) 12 (3-52) 
 
< 0.001 
 
Doses of hydrochlorothiazide 
[mg] 
  0.550 
  12.5 22 (15.83) 7 (10.77)  
  25 104 (74.82) 53 (81.54)  
  50 13 (9.35) 5 (7.69)  
Co-morbid diseases    
  Diabetes mellitus 55 (39.57) 38 (55.88) 0.027 
  Dyslipidemia 54 (38.85) 18 (26.47) 0.079 
  Stroke  12 (8.63) 6 (8.82) 0.964 
  Coronary artery disease 8 (5.76) 10 (14.71) 0.032 
  Cirrhosis  3 (2.16) 4 (5.88) 0.221 
  COPD 1 (0.72) 3 (4.41) 0.105 
  Asthma 9 (6.47) 2 (2.94) 0.346 
  Gout 7 (5.04) 7 (10.29) 0.157 
  OSA 4 (2.88) 2 (2.94) 0.999 
  BPH 4 (2.88) 3 (4.41) 0.686 
  VHD 4 (2.88) 4 (5.88) 0.443 
  Old tuberculosis 4 (2.88) 2 (2.94) 0.999 
  Cancer 13 (9.35) 3 (4.41) 0.274 
Note: Data presented as numbers (percentage) or median (1st to 3rd quartile range); BMI — body mass 
index; ACEI — angiotensin-converting enzyme innhinitor; ARB — angiotensin II receptor blocker; 
COPD — chronic obstructive pulmonary disease; OSA — obstructive sleep apnea; VHD —valvular 
heart disease 
 
Table 2. Laboratory results of hypertensive patients treated with hydrochlorothiazide categorized 
by presence of symptomatic hyponatremia (hypoNa)  
Factors No hypoNa 
(n = 139) 
HypoNa 
(n = 68) 
p value 
Hematocrit (%) 37.6 (33.8–41.0) 32.2 (28.6–37.3) < 0.001 
White blood cells [x 103/mm3] 7800 (6500–9270) 7150 (6150–8700) 0.109 
Platelet [x 106/mm3] 261 (226–314) 280 (216–336) 0.524 
Glucose [mg/dL] 106 (93–130) 132 (109–180) < 0.001 
BUN [mg/dL] 13.85 (10.00–
18.45) 
15.90 (11.10–23.80) 0.025 
Cr [mg/dL] 0.9 (.07–1.1) 1.0 (0.8–1.3) 0.112 
eGFR [mL/min/1.732] 70.06 (53.74–
92.87) 
47.81 (31.68–69.33) < 0.001 
Uric acid [mg/dL] 6.0 (4.9–7.1) 4.5 (3.7–5.6) < 0.001 
Sodium [mEq/L] 140 (137–141) 117 (114–121) < 0.001 
Potassium [mEq/L] 4.0 (3.7–4.4) 3.8 (3.2–4.3) 0.001 
HCO3 [mEq/L] 25.2 (23.2–27.1) 24.5 (22.4–26.3) 0.158 
Chloride [mEq/L] 100 (97–103) 80 (75–86) < 0.001 
Calcium [mg/dL] 9.1 (8.6–9.4) 8.8 (8.3–9.2) 0.105 
Phosphate [mg/dL] 3.6 (3.1–3.9) 3.3 (2.6–3.6) 0.028 
Cholesterol [md/dL] 178 (153–210) 181 (146–214) 0.559 
Albumin [g/dL] 4.2 (3.7–4.4) 3.9 (3.5–4.2) 0.012 
Globulin [g/dL] 3.1 (2.7–3.6) 3.2 (2.9–3.5) 0.606 
Total bilirubin [mg/dL] 0.5 (0.4–0.7) 0.7 (0.4–1.2) 0.016 
Direct bilirubin [mg/dL] 0.2 (0.1–0.3) 0.2 (0.1–0.3) 0.566 
ALT [U/L] 21 (15–26) 23 (17–40) 0.070 
AST [U/L] 22 (18–30) 31 (24–49) < 0.001 
Alkaline phosphatase [U/L] 75 (62–94) 82 (71–100) 0.172 
Magnesium [mg/dL] 2.0 (1.9–2.2) 1.8 (1.5–1.9) < 0.001 
Triglyceride [mg/dL] 133 (104–178) 110 (75–177) 0.554 
HDL–C [mg/dL] 53 (43–61) 47 (41–59) 0.223 
LDL–C [mg/dL] 113 (95–141) 86 (72–156) 0.207 
Urine sp.gr. 1.014 (1.009–
1.018) 
1.010 (1.005–1.011) < 0.001 
Urine pH 6.0 (5.5–6.5) 7.0 (6.5–7.0) < 0.001 
Note: Data presented as median (1st to 3rd quartile range); BUN — blood urea nitrogen; Cr — creatinine; 
eGFR — estimated glomerular filtration rate; HCO3 — bicarbonate; ALT — alanine aminotransferase; 
AST — aspartate aminotransferase; UACR — urine albumin-creatinine ratio; HDL — high density 
lipoprotein; LDL — low density lipoprotein 
Table 3. Factors associated with symptomatic hyponatremia in hypertensive patients treated with 
hydrochlorothiazide (HCTZ) 
Factors Unadjusted odds ratio 
(95% CI) 
Adjusted odds ratio 
(95% CI) 
Age (years) 1.062 (1.031, 1.093) 1.026 (0.954, 1.105) 
Male sex 0.515 (0.267, 0.993) 0.099 (0.013, 0.764) 
BMI 0.834 (0.761, 0.914) 0.683 (0.542, 0.860) 
Duration of HCTZ 0.986 (0.977, 0.995) 0.975 (0.951, 1.001) 
Dose of HCTZ 1.162 (0.625, 2.160) 6.981 (0.876, 55.617) 
Plasma glucose 1.015 (1.006, 1.024) 1.030 (1.009, 1.051) 
GFR 0.978 (0.967, 0.989) 0.998 (0.970, 1.027) 
Serum albumin 0.558 (0.333, 0.936) 0.122 (0.027, 0.532) 
CI — confidence interval; BMI — body mass index; GFR — glomerular filtration rate 
